SynthesisActa psychiatrica Scandinavica2026
The Effect of Benzodiazepines on Catatonia: A Systematic Review and Meta-Analysis.
Synthesis in Acta psychiatrica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCatatonia is a complex psychomotor syndrome associated with various psychiatric and somatic underlying disorders. Current treatment protocols include benzodiazepines and electroconvulsive therapy (ECT). Despite their widespread use, systematic evidence regarding efficacy and optimal benzodiazepine dosage remains limited. This systematic review and meta-analysis aims to evaluate the effectiveness of benzodiazepines in treating catatonia.
methodsA comprehensive search of PubMed, Embase, APA PsychInfo, and Cochrane central identified studies reporting benzodiazepine treatment outcomes in catatonia. Screening and data extraction were done by two independent researchers. A targeted meta-analysis was performed on cases and studies that provided clear documentation of the Bush Francis Catatonia Rating Scale (BFCRS) scores before and after treatment, along with well-defined dosage regimens. Finally, the relationship between dosage and BFCRS improvement was explored.
resultsOf 1336 screened articles, 53 met inclusion criteria. Most were case series using lorazepam (a benzodiazepine) to treat catatonia, with dosages ranging from 2 to 60 mg/day with a median dose of 8 mg/day. The overall remission rate was 55%; overall response was 77%. Treatment duration varied, but predominantly did not exceed 1 week. Our targeted analysis showed an overall effect of -11.88 points on the BFCRS when a benzodiazepine was used in the treatment of catatonia with a Cohen's d = -3.15. In a meta regression, no significant dose-response relationship was found.
conclusionBenzodiazepines are highly effective for treating catatonia, but optimal dosing remains unclear. The absence of a clear dose-effect relationship highlights the need for individualized treatment strategies and well-designed controlled studies to establish stronger evidence-based treatment guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.